Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries

Drugs and Aging

Volumn 21, Issue 10, 2004, Pages 677-686

  Caro, Jaime ^a,b   Salas, Maribel ^a   Ward, Alexandra ^a   Getsios, Denis ^c   Migliaccio Walle, Kristen ^a   Garfield, Frances ^a  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Caro Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; CANADA; CAREGIVER; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; FEMALE; FINLAND; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEW ZEALAND; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SOCIAL WORK; SWEDEN; UNITED KINGDOM;

ALZHEIMER DISEASE; AUSTRALASIA; CANADA; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EUROPE; GALANTAMINE; HUMANS; LONG-TERM CARE; MODELS, ECONOMIC; PLACEBOS;

EID: 4344659151     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421100-00005     Document Type: Article

References (54)

1. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736-48
2. Demography Dementia Worldwide. Alzheimer's Society [on-line]. Available from URL: http://www.alzheimers.org.uk/ News_and_Campaigns/Policy_Watch/ demography.htm [Accessed 2004 Jan 6]
3. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998; 159: 457-65
4. Bosanquet N, May J, Johnson N. Alzheimer's disease in the UK: burden of disease and future care. Health Policy Review No. 12. London: Imperial College of Science and Technology, 1998
5. McDonnell J, Redekop WK, van der Roer N, et al. The cost of treatment of Alzheimer's disease in the Netherlands. Pharmacoeconomics 2001; 19: 379-90
6. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15: 365-75
7. Rice DP, Fillit HM, Max W, et al. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 2001; 7: 809-18
8. Walsh J, Welch G, Larson E. Survival of outpatients with Alzheimer's type dementia. Ann Intern Med 1990; 113: 429-34
9. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45
10. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318: 633-8
11. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001; 4: CD001747
12. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord 1999; 13: S9-S19
13. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54 (12): 2261-8
14. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
15. Wilcock GK, Lilienfeld S, Gaens E, et al., on behalf of the Galantamine International Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomised controlled trial. BMJ 2000; 321: 1-7
16. Caro D, Getsios JJ, Migliaccio-Walle K, et al., for the AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD) based on the need for full time care. Neurology 2001; 57: 964-71
17. Ward A, Caro JJ, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003; 18: 740-7
18. Getsios D, Caro JJ, Caro G, et al., for the AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001; 57: 972-8
19. Caro JJ, Salas M, Ward A, et al., for the AHEAD Study Group. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 787: 1-12
20. Garfield FB, Getsios D, Caro JJ, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20: 629-37
21. Stern Y, Tan MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277: 806-12
22. Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2002; 2: 6
23. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-4
24. Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999; 37 (1): 27-32
25. Drummond MF, O'Brien B, Stoddarts GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford Medical Publications, 1997: 6-26
26. Rosewarne R, Opie J, Brace A, et al. Care needs of people with dementia living in residential care facilities No. 30 Aged and Community Care Service Development and Evaluation Reports Commonwealth Department of Health and Family Services. Canberra (ACT): AGPS, 1997
27. Community Aged Care Packages in Australia 1999-00. A statistical overview AIHW Cat No. AGE20, May 2001 (Aged Care Statistics Series Number 10). Canberra (ACT): AIHW, 2001
28. Human Services 1997. Home and Community Care Unit Cost Survey. A descriptive analyses of survey findings aged, community and mental health division. Melbourne (VIC): Victorian Government Department of Human Services, 1997 Feb
29. Sulkava R, Wikstrom K, Aromaa A, et al. Prevalence of severe dementia in Finland. Neurology 1985; 35: 1025-9
30. Juva K, Sulkava R, Erkinjuntti T, et al. The demented elderly in the City of Helsinki: functional capacity and placement. J Am Geriatr Soc 1992; 40: 1146-50
31. Herco Oy Ltd. Unit costs based on a weighted average of unit costs found in health centers located within the Helsinki and Uusimaa Hospital District: Finnish Hospital Districts and health centers in Southern Finland, Helsinki: Herco Oy Ltd, 1999 (Data on file)
32. Campbell AJ, McCosh LM, Reinken J, et al. Dementia in old age ant the need for services. Age Ageing 1983; 12: 11-6
33. National Health Committee. Guidelines for the support and management of people with dementia. Wellington, New Zealand: National Health Advisory Committee on Health and Disability, 1997
34. Auckland Healthcare 2001. Moving into Residential Care. Residential Information Service, Community Health Services, Auckland District Health Board. Auckland, New Zealand: Auckland District Health Board, 2001
35. Martin J, Meltzer H, Elliot D. The prevalence of disability among adults: OPC surveys of disability in Great Britain. Report 1. London: HMSO, 1988
36. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's Disease care. Health Aff (Millwood) 1993 Summer; 12 (2): 164-75
37. Netten A, Dennett J, Knight J. Unit costs of health and social care. Personal Social Services Research Unit (PSSRU). Canterbury: University of Kent, 1998
38. The Canadian Study of Health and Aging. Patterns of caring for people with dementia in Canada. Can J Aging 1994; 13: 470-87
39. Department of Health. Community Care Statistics 2000: residential personal social services for adults in England, Department of Health. Statistical bulletin 2000/028. London: Department of Health, 2000
40. Netten A, Darton R, Bebbington A, et al. Residential or nursing home care?: the appropriateness of placement decisions. Aging Soc 2001; 21: 3-23
41. Dijkstra A, Sipsma DH, Dassen TWN. Care dependency and survival among female patients with Alzheimer's disease: a two-year follow-up. Croat Med J 1998; 39: 365-70
42. Boersma F, Ebfsting JA, Van den Brink W, et al. Care services for dementia patients: predictors for service utilization. Int J Geriatr Psychiatry 1997; 12: 1119-26
43. Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Dis 1997; 11: 191-200
44. Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12: 857-61
45. Annerstedt L. Group-living care: an alternative for the demented elderly. Dement Geriatr Cogn Disord 1997; 8: 136-42
46. Aro S, Noro A, Salinto M. Deinstitutionalization of the elderly in Finland, 1981-91. Scand J Soc Med 1997 Jun; 25 (2): 136-43
47. National Institute of Clinical Excellence, Special Health Authority. Review of completed technology appraisals 2000/ 2001. Item 3. Annual Public Meeting of the National Institute of Clinical Excellence; 2001 Jul 18; Cardiff, 1-9
48. Wimo A, Mattson B, Krakau I, et al. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995; 11: 49-65
49. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry 1997; 12: 841-56
50. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer's disease: how can we manage the costs? Pharmacoeconomics 2000; 18: 215-23
51. Max W. Drug treatments for Alzheimer's disease: shifting the burden of care. CNS Drugs 1999; 11: 363-72
52. Max W, Weber P, Fox P. Alzheimer's disease: the unpaid burden of caring. J Aging Health 1995; 7: 179-99
53. Wilkinson D. Caregiver burden in Alzheimer's disease: the impact of cholinesterase inhibitors. CPD Bulletin Old Age Psychiatry 2001; 2: 76-9
54. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15 (2): 79-87